Clinical Trial Update: Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GI-4000 in combination with gemcitabine versus placebo for non-metastatic, post-resection pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GI-4000
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: GlobeImmune | Conditions: Pancreas Cancer | Phase 2 | Status: COMPLETED